A research team headed by two School of Medicine professors has developed a new method for tracking adverse drug interactions using queries from Internet search engines like Google and Bing. The team’s discovery offers an alternative to the Food and Drug Administration’s (FDA) Adverse Event Reporting System (AERS).
Cuéllar said that growing up along the U.S.-Mexico border had a profound influence on his understanding of the world and prompted his desire to study politics and governance.
Palo Alto resident Christopher Bui is suing the Stanford Blood Center because of an infection he said he acquired after donating blood on April 10, 2008.
Researchers from the Stanford School of Medicine recently created an algorithm that suggests that inadvertent impacts of drug use vastly exceed those detailed by seemingly exhaustive industry labeling.
Using a computer model of the hepatitis C disease, Stanford researchers have shown that two new drugs intended to target the virus are cost-effective for patients suffering from advanced hepatitis C, despite some significant side effects.
Two studies from the School of Medicine, published Monday in Annals of Internal Medicine, revealed that an expensive blood-clotting drug intended only for hemophilia patients has been mainly prescribed for patients without this disorder. This practice, however, may pose certain health risks.
Searsville Dam causes flood of letters … Stanford nabs federal grants … Pediatrics prof helps out overseas … A First Amendment rights case settles … Stanford news from around the web for Friday, July 23, 2010.
The Food and Drug Administration (FDA) on Thursday approved Provenge, a new treatment for prostate cancer that was originally developed by Stanford researchers in the 1990s.